Incyte (NASDAQ:INCY) Stock Rating Lowered by Zacks Research

Posted by Geri Gentry on Oct 16th, 2026

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Wednesday, Zacks reports.

A number of other equities analysts have also weighed in on INCY. Canaccord Genuity Group began coverage on shares of Incyte in a research report on Thursday, August 20th. They set a “buy” rating and a $152.00 target price for the company. Sanford C. Bernstein reissued a “market perform” rating and issued a $104.00 price target on shares of Incyte in a research report on Thursday, August 13th. BMO Capital Markets reissued a “market perform” rating on shares of Incyte in a research report on Tuesday, September 1st. Barclays upped their price target on shares of Incyte from $134.00 to $139.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Finally, Stifel Nicolaus upped their price target on shares of Incyte from $145.00 to $157.00 and gave the company a “buy” rating in a research note on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $128.20.

Check Out Our Latest Stock Analysis on INCY

Incyte Stock Performance

INCY stock opened at $113.27 on Wednesday. The stock has a fifty day moving average of $122.11 and a 200-day moving average of $110.75. Incyte has a fifty-two week low of $84.02 and a fifty-two week high of $132.60. The company has a market capitalization of $22.96 billion, a price-to-earnings ratio of 14.43, a PEG ratio of 3.78 and a beta of 0.74.

Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.15 by $0.94. Incyte had a return on equity of 29.93% and a net margin of 27.71%. The business had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the previous year, the business posted $1.57 EPS. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. Equities analysts predict that Incyte will post 2.40 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Patrick Mayes sold 41,899 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the sale, the executive vice president owned 61,441 shares of the company’s stock, valued at approximately $7,339,741.86. This represents a 40.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo Cagnoni sold 10,801 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total value of $1,356,173.56. Following the completion of the transaction, the insider owned 183,200 shares of the company’s stock, valued at approximately $23,002,592. This represents a 5.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 16.20% of the company’s stock.

Institutional Investors Weigh In On Incyte

A number of institutional investors and hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. grew its stake in Incyte by 1,555.7% during the third quarter. Assenagon Asset Management S.A. now owns 121,825 shares of the biopharmaceutical company’s stock valued at $14,783,000 after acquiring an additional 114,467 shares in the last quarter. Curated Wealth Partners LLC purchased a new stake in Incyte in the 3rd quarter worth approximately $782,000. SBE LLC DBA Cedar Cove Wealth Partners purchased a new stake in Incyte in the 3rd quarter worth approximately $349,000. Mather Group LLC. lifted its stake in Incyte by 13.5% in the 3rd quarter. Mather Group LLC. now owns 1,157 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 138 shares in the last quarter. Finally, Sanders Morris Harris LLC bought a new position in Incyte in the 3rd quarter valued at $607,000. 96.97% of the stock is owned by hedge funds and other institutional investors.

About Incyte

(Get Free Report)

Incyte Corporation is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases, with an emphasis on oncology, hematology and inflammatory or dermatologic conditions. The company conducts research through internal programs and collaborations with academic institutions, biotechnology companies and pharmaceutical partners.

Incyte’s marketed portfolio includes Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain myelofibrosis, polycythemia vera and graft-versus-host disease indications, and Opzelura (ruxolitinib) cream for certain inflammatory skin conditions.